Relationships among Serum CA15-3 Tumor Marker, TNM Staging, and Estrogen and Progesterone Receptor Expression in Benign and Malignant Breast Lesions

  • Atoum, Manar (Department of Medical Laboratories, Faculty of Allied Health Sciences, Hashemite University) ;
  • Nimer, Nisreen (Department of Medical Laboratories, Faculty of Allied Health Sciences, Hashemite University) ;
  • Abdeldayem, Sawsan (Medical Laboratory Sciences. King Hussein Medical Center) ;
  • Nasr, Hamzah (Reference Medical Laboratories)
  • Published : 2012.03.31


Serum tumor marker CA15-3 is widely used in follow-up for assessment of breast cancer prognosis. The aim of this study was to evaluate levels among healthy females and patients, to assess differences with tumor stage and grade, and to determine the relationship with estrogen and progesterone receptor expression. One hundred and thirty six Jordanian females were enrolled in this study: Forty-five were healthy females; seventy-two were diagnosed with breast cancer and nineteen diagnosed with benign breast lesions. Elevated serum CA15-3 level was significantly observed among breast cancer patients ($37.95{\pm}6.65$) compared to both healthy ($14.97{\pm}0.8$) and benign females ($12.30{\pm}1.55$), but no significant association was detected between serum CA15-3 level and age of cancer onset, menarche age, menopause age, parity and BMI. Decreased CA15-3 level was significantly associated with hormone therapy and oral contraceptive consumption among breast cancer patients. Significantly elevated CA15-3 serum levels were found among grade II, III and stage II and III breast cancer females compared to normal healthy females. Elevated CA15-3 serum levels were also found among ER+/PR+($54.242{\pm}7.89$) and ER+/PR-($37.08{\pm}8.22$) compared to healthy control females.


  1. Anonymous (1996). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol, 14, 2843-77.
  2. Bensouda Y, Andre F, Boulet T, et al (2009). Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status. Bull Cancer, 96, 923-8
  3. Berruti A, Tampellini M, Torta M, et al (1994). Prognostic value in predicting overall survival of two mucinous markers: CA15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer, 30, 2082-4
  4. Brekelmans CT (2003). Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol, 15, 63-8.
  5. Busetto M, Vianello L, Franceschi R, Bolzan M (1995). CA 15-3 value and neoplastic disease predictivity in the follow-up for breast cancer. Tumour Biol, 16, 243-53.
  6. Cengiz B, Atabekoglu C, Cetinkaya E, Cengiz SD (2003). Effect of hormone replacement therapy on serum levels of tumor mark¬ers in healthy postmenopausal women. Maturitas, 46,301-6.
  7. Cheung K, Graves CRL, Robertson JFR (2000). Tumor marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev, 26,91-102.
  8. Coveney EC, Geraghty JG, Sherry F, et al (1995). The clinical value of CEA and CA 15-3 in breast cancer management. Int J Biol Markers, 10, 35-41.
  9. Crump C, McIntosh MW, Urban N, Anderson G, Karlan BY (2000). Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev, 9, 1107-11.
  10. Dehaghani AS, Ghiam AF, Hosseini M, Mansouri S, Ghader A (2007). Factors Influencing Serum Concentration of CA125 and CA15-3 in Iranian Healthy Postmenopausal Women. Pathology Oncol Res, ?, 13360-364.
  11. Duffy MJ (1999). CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem, 36, 579-86.
  12. Duffy MJ (2006). Serum tumor markers in breast cancer: Are they of clinical value? Clinical Chemistry, 52, 345-51
  13. Elston CW, Ellis IO, Pinder SE (1999). Pathological prognostic factors in breast cancer. Crit Rev Oncol Haematol, 31, 209-23.
  14. Gang Y, Adachi I, Ohkura H, (1985). CA15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies. Gan To Kagaku Ryoho, 12, 2379-86
  15. Gion M, Boracchi P, Dittadi R, et al (2002). Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer, 38, 1181-8.
  16. Hayes DF, Mesa Tejada R, Papsidero L, et al (1991). Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol, 9, 1113-23.
  17. Hayes DF, Zurawski VR, Kufe DW (1986). Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol, 4, 1542-50.
  18. Jordan breast cancer program:
  19. Kikuchi K, Uematsu Y, Takada Y, et al (1987). Evaluation of tumor marker CA15-3 in breast cancer. Gan To Kagaku Ryoho, 14, 3095-100.
  20. Kobayashi S, Iwase H, Karamatsu S, et al (1989). The clinical value of serum CA15-3 assay postoperatively in breast cancer patients. Jpn J Surg, 19, 278-82.
  21. Kochańska Dziurowicz A, Pasich R, Stanjek A, Gaweł Szostek V, T Jankowski (2000). Serum concentration of selected neoplasm markers: CA15-3, TPS and CEA in women with diagnosed breast benign disease. Ginekol Pol, 71, 1139-43
  22. Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M (2004). Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res, 24, 3221-4.
  23. McLaughlin R, McGrath J, Grimes H, Given HF (2000). The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers, 15, 340-2.
  24. Molina R, Jo J, Zanón G, et al (1996). Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. Br J Cancer, 74, 1126-31.
  25. Molina R, Jo J, Filella X, et al (1999). C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res, 19, 2551-5.
  26. Nicolini A (2000). Carpi A. Postoperative follow-up of breast cancer patients: overview of progress in the use of tumor markers. Tumor Biol, 21, 235-48.
  27. Pike MC, Pearce CL, Wu AH (2004) Prevention of cancers of the breast, endometrium and ovary. Oncogene, 23, 6379-91.
  28. Rymer J, Morris EP (2000). Extracts from "Clinical evidence": Menopausal symptoms. BMJ, 321, 1516-9.
  29. Seregni E, Botti C, Bajetta E, et al (1999). Bombardieri E: Hormonal regulation of MUC1 expression. Int J Biol Markers, 14, 29-35.
  30. Shering SG, Sherry F, McDermott EW, et al (1998). Preoperative CA15-3 concentrations predict outcome of patients with breast carcinoma. Cancer, 83, 2521-7.<2521::AID-CNCR17>3.0.CO;2-A
  31. Singletary SE, Allred C, Ashley P, et al (2002). Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol, 20, 3628-36.
  32. Tampellini M, Berruti A, Gerbino A, et al (1997). Relationship between CA15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer, 75, 698- 702.
  33. Taylor PJ, Burchell JM, Plunkett T, et al (2002). MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia, 7, 209-21.
  34. Theriault RL, Hortobagyi GN, Fritsche HA, et al (1989). The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy. Cancer, 63, 828-35.<828::AID-CNCR2820630506>3.0.CO;2-3
  35. Thompson JA, Grunert F, Zimmermann W (1991). Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal, 5, 344-66.
  36. Thriveni K, Krishnamoorthy L, Ramaswamy G (2007). Correlation study of carcinoembryonic antigen & cancer antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biol, 22, 57-60

Cited by

  1. Breast Cancer in Morocco: A Literature Review vol.15, pp.3, 2014,
  2. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening vol.17, pp.1, 2016,
  3. Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort vol.10, pp.1, 2017,